Browsing by Author "COŞKUN, NECMİYE FUNDA"

Now showing 1 - 20 of 42

Ace gene i/d polymorphism and risk of sarcoidosis development in Turkish patients
(Turkish Assoc Tuberculosis & Thorax, 2012-01-01) Yılmaz, Dilber; Karkucak, Mutlu; Coşkun, Funda; COŞKUN, NECMİYE FUNDA; Yakut, Tahsin; Uzaslan, Esra Kunt; UZASLAN, AYŞE ESRA; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Genetik Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim Dalı.; 0000-0003-3604-8826; AAD-1271-2019; AAI-1004-2021; ABI-5648-2022
Introduction: Etiology of sarcoidosis is unknown but the prevalence of disease in different ethnic groups and identical twins, family characteristics indicate that genetic predisposition is a possible factor. The angiotensin-converting enzyme (ACE) has been implicated in the pahophysiology of sarcoidosis. The aim of this study is to investigate the influence of a polymorphism in I/D (Insertion/Deletion) of the ACE gene on the susceptibility to sarcoidosis.Patients and Methods: Our study included 70 Turkish patients who had histopathological diagnosis of sarcoidosis and 69 healthy age and sex matched control subjects. Polymerase chain reaction was used for analysing an I/D polymorphism in the gene coding for ACE. Genotyping was done according to bands that were formed on the agarose gel electrophoresis. Chi-square test was used for statistical analysis and p<0.05 was accepted as significance.Results: Although the D allele was more frequent in the sarcoidosis patients group, the frequency of the D allele was 67% and 54% respectively in the sarcoidosis and the control group. No significant difference in allele frequencies of I/I, I/D, D/D polymorphisms was observed between the sarcoidosis and control group (p> 0.05). Similarly allele frequencies of I/I, I/D, D/D polymorphisms was not different between sarcoidosis patients with extrapulmonary involvement and sarcoidosis patients without extrapulmonary involvement (p> 0.05).Conclusion: Our findings have showed that contribution of ACE gene polymorphisms to susceptibility of disease development in Turkish sarcoidosis patients is not different from the healthy control subjects.
Anxiety and depression levels of healthcare workers during covid-19 pandemic
(European Respiratory Soc Journals, 2021-09-05) Turan, Muzaffer Onur; Demirci, Nilgun Yilmaz; Ak, Guntulu; Akcay, Sule; Akturk, Ulku Aka; Bilaceroglu, Semra; ; Kokturk, Oguz; Mirici, Arzu; Cengiz, Ozdemi. R.; Sen, Nazan; Yilmaz, Ulku; Coşkun, Funda; COŞKUN, NECMİYE FUNDA; Bursa Uludağ Üniversitesi/Tıp Fakültesi.; 0000-0001-6160-3778; 0000-0001-8849-193X; 0000-0002-9703-9598; 0000-0003-3604-8826; 0000-0002-4171-7484; AFP-3587-2022; O-8969-2018; C-9348-2014; HKN-2974-2023; JAI-8635-2023; AAD-1271-2019
Associated factors with short-term mortality in pulmonary thromboembolism patients
(European Respiratory, 2015-09-01) Çetinoğlu, Ezgi Demirdöğen; Dilektaşlı, Aslı Görek; Güçlü, Özge Aydın; Özkaya, Güven; Coşkun, Funda; Ursavaş, Ahmet; Karadağ, Mehmet; Çetinoğlu, Ezgi Demirdöğen; GÖREK DİLEKTAŞLI, ASLI; AYDIN GÜÇLÜ, ÖZGE; ÖZKAYA, GÜVEN; COŞKUN, NECMİYE FUNDA; URSAVAŞ, AHMET; KARADAĞ, MEHMET; Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim Dalı; Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı; 0000-0002-7400-9089; 0000-0001-7099-9647; 0000-0003-1005-3205; 0000-0003-0297-846X; 0000-0003-3604-8826; 0000-0002-9027-1132; JPK-7012-2023; AAG-8744-2021; AAI-3169-2021; AAD-1271-2019; A-4421-2016; AAG-9930-2019; AAH-9812-2021; DTT-7416-2022
Association of cytotoxic T lymphocyte subsets with disease severity in Covid-19
(Wiley, 2021-08-01) Kızmaz, Muhammed Ali; Çağan, Eren; Şimşek, Abdurrahman; Dombaz, Fatma; Tezcan, Gülçin; Aşan, Ali; Demir, H. İbrahim; Bal, S. Haldun; Ermiş, Diğdem Yöyen; Coşkun, Necmiye Funda; Akalın, E. Halis; Oral, Haluk Barbaros; Budak, Ferah; Kızmaz, Muhammed Ali; ŞİMŞEK, ABDURRAHMAN; Dombaz, Fatma; TEZCAN, GÜLÇİN; Demir, H. İbrahim; BAL, SALİH HALDUN; YÖYEN ERMİŞ, DİĞDEM; COŞKUN, NECMİYE FUNDA; AKALIN, EMİN HALİS; ORAL, HALUK BARBAROS; BUDAK, FERAH; Bursa Uludağ Üniversitesi/Tıp Fakültesi/İmmünoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Diş Hekimliği Fakültesi/Temel Bilimler Bölümü.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Klinik Mikrobiyoloji ve Enfeksiyon Hastalıkları Anabilim Dalı.; 0000-0001-5334-7911; 0000-0001-8850-0269; 0000-0001-7288-3250; 0000-0002-5956-8755; 0000-0002-8856-7356; 0000-0001-7585-7971; 0000-0003-3604-8826; 0000-0001-7530-1279; 0000-0003-0463-6818; 0000-0001-7625-9148; 0000-0003-3604-8826; HKN-2347-2023; IZP-9398-2023; AAH-3843-2020; F-4657-2014; AAG-7381-2021; K-7285-2012; AAU-8952-2020; DWR-5356-2022; GPN-1473-2022; KBR-5535-2024; GYL-2038-2022; AAD-1271-2019
Atopy and allergic diseases frequency in stable sarcoidosis patients
(Wiley, 2015-12-01) Uzaslan, Ayşe Esra; Savaş, Nazan Nalcı; Uzaslan, Esra; Ediger, Dane; Coşkun, Funda; Ursavaş, Ahmet; Gözu, Oktay; Savaş, Nazan Nalcı; UZASLAN, AYŞE ESRA; EDİGER, DANE; COŞKUN, NECMİYE FUNDA; URSAVAŞ, AHMET; Gözu, Oktay; Uludağ Üniversitesi/Tıp Fakültesi; 0000-0002-2954-4293; 0000-0003-3604-8826; AAD-1271-2019; AAI-3169-2021; AAE-9142-2019; EDM-6718-2022; IOL-2975-2023; CDI-1977-2022; JLC-5863-2023
AVAPS-NIV treatment in hypercapnic respiratory failure with insufficient response to fixed-level PS-NIV
(Türk Tüberküloz ve Toraks, 2022-01-01) Öztürk, Nilüfer Aylın Acet; Güçlü, Özge Aydın; Demirdöğen, Ezgi; Dilektaşlı, Asli Görek; Maharramov, Shahriyar; Coşkun, Funda; Uzaslan, Esra; Ursavaş, Ahmet; Karadağ, Mehmet; ACET ÖZTÜRK, NİLÜFER AYLİN; AYDIN GÜÇLÜ, ÖZGE; DEMİRDÖĞEN, EZGİ; GÖREK DİLEKTAŞLI, ASLI; Maharramov, Shahriyar; COŞKUN, NECMİYE FUNDA; UZASLAN, AYŞE ESRA; URSAVAŞ, AHMET; KARADAĞ, MEHMET; Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim Dalı; 0000-0002-6375-1472; 0000-0003-1005-3205; 0000-0002-7400-9089; 0000-0001-7099-9647; 0000-0003-3604-8826; 0000-0002-9027-1132; AAI-3169-2021; AAD-1271-2019; AAG-8744-2021; JPK-7012-2023; DTT-7416-2022; DDT-7334-2022
Introduction: Noninvasive ventilation (NIV) for acute hypercapnic respiratory failure (AHRF) is an established treatment modality. Current evidence does not conclude any superiority between fixed pressure support (PS) and aver-age volume-assured pressure support (AVAPS) modes. However, given the ability of rapid PaCO2 decline in AVAPS mode, we hypothesized that COPD patients with AHRF who did not show the desired reduction in PaCO2 with fixed-level PS-NIV might benefit from the AVAPS mode.Materials and Methods: Patients admitted to the non-ICU pulmonary ward with acute exacerbation of COPD (AECOPD) and AHRF were included con-secutively in this observational study. Patients with hypercapnic respiratory failure due to obesity-hypoventilation, neurological diseases, or chest wall deformities were excluded. All patients started NIV treatment with fixed pres-sure support (PS) and patients who did not reach clinical and laboratory stability under PS-NIV treatment were switched to the average volume -as-sured pressure support (AVAPS) mode of NIV.Results: Thirty-five COPD patients with hypercapnic respiratory failure were included. Under PS-NIV treatment, 14 (40%) patients showed a 17.9 (-0.0-29.2) percent change in terms of PaCO2 , meaning no improvement or worsening. Therefore, these patients were treated with AVAPS mode. Arterial PaCO2 and pH levels significantly improved after AVAPS-NIV administration. AVAPS-NIV treatment created a significantly better PaCO2 change rate than using PS-NIV (-11.4 (-22.0 --0.5)vs 8.2 (-5.3-19.5), p= 0.02]. Independent predictors of AVAPS mode requirement were higher Charlson Comorbidity Index (OR= 1.74 (95% CI= 1.02-2.97)] and higher PaCO2 upon admission (OR= 1.18 (95% CI= 1.03-1.35)]. Thirteen (92.8%) patients reaching signif-icant clinical stability with AVAPS-NIV were able to return to fixed-level PS-NIV and maintain acceptable PaCO2 levels.Conclusion: Our study demonstrated that patients can benefit from AVAPS-NIV despite insufficient response to fixed-level PS-NIV.
Changes in myocardial performance in sarcoidosis patients
(Amer, 2015-10-01) Kederli, Aysel; Güllülü, Sümeyye; Coşkun, Funda; Yılmaz, Dilber; Uzaslan, Esra; Kederli, Aysel; GÜLLÜLÜ, NAZMİYE SÜMEYYE; COŞKUN, NECMİYE FUNDA; Yılmaz, Dilber; UZASLAN, AYŞE ESRA; Uludağ Üniversitesi/Tıp Fakültesi/Kardiyoloji Anabilim Dalı; 0000-0003-3604-8826; AAD-1271-2019; CZE-7153-2022; EXG-3181-2022; EGU-1690-2022; CDI-1977-2022
Clinical effectiveness of nebulised budesonide in the treatment of acute asthma attacks
(Turkish Assoc Tuberculosis & Thorax, 2006-01-01) Ediger, Dane; COŞKUN, NECMİYE FUNDA; EDİGER, DANE; Coskun, Funda; Kunt Uzaslan, Esra; Gürdal Yüksel, Eser; Ege, Ercüment; Gözü, Oktay; Karadag, Mehmet; KARADAĞ, MEHMET; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim Dalı.; 0000-0002-2954-4293; 0000-0003-3604-8826; 0000-0002-9027-1132; AAG-8744-2021; AAD-1271-2019; AAE-9142-2019
Nebulized budesonide (NB) might offer topical anti-inflammatory activity and be an alternative to systemic corticosteroid (SC) in the treatment of acute asthma. The aim of this study was to compare the effect of NB with SC on lung function and clinical findings of adult patients with acute asthma. Thirty patients admitted to clinic with asthma attack (F/M:26/4; mean age: 47.1 +/- 2.1 years) were enrolled to the study. The patients were randomized into three groups; Group I were treated with NB alone (4 mg/day), Group II SC alone (1 mg/kg/day methylprednisolone), Group III NB plus SC. Pulmonary functions and respiratory symptom scores were measured and recorded before and during 7 days of study. Spirometric parameters significantly improved in all groups at 7th day significantly (p< 0.05) without a difference among groups (p> 0.05). FEV 1 % levels increased significantly at the first day of study in Group I and III (p< 0.05), but didn't change in Group II until 5th day of study. The mean symptom scores decreased significantly at the second day in Group I (p< 0.05), and at the 4th day in other groups. NB with or without SC improved successfully airway obstruction and symptoms in patients hospitalized with acute asthma attack as the 1st treatment day in comparison with SC alone and this effect lasted for 7 days. Regarding the superior safety profile and comparable efficacy with SC, NB might be an alternative to the patients with moderate-severe asthma attacks.
Clinical, functional characteristics and exercise capacity of the frequent exacerbator copd phenotype
(Amer Thoracic Soc, 2015-01-01) Uzaslan, Esra; Dilektaşlı, Aslı Görek; Çetinoğlu, Ezgi Demirdogen; Budak, Ferah; Coşkun, Funda; Ursavas, Ahmet; Ege, Ercüment; UZASLAN, AYŞE ESRA; GÖREK DİLEKTAŞLI, ASLI; Çetinoğlu, Ezgi Demirdogen; BUDAK, FERAH; COŞKUN, NECMİYE FUNDA; URSAVAŞ, AHMET; Ege, Ercüment; Uludağ Üniversitesi; 0000-0001-7099-9647; 0000-0002-7400-9089; 0000-0001-7625-9148; 0000-0003-3604-8826; JPK-7012-2023; F-4657-2014; AAD-1271-2019; AAI-3169-2021; IZP-9398-2023; CDI-1977-2022; DTT-7416-2022; AAH-9812-2021
Coagulopathy and COVID-19
(Kare Yayınevi, 2020-05-18) Yazıcı, Onur; Bozkuş, Fulsen; Demirci, Nilgün; Gülhan, Pınar Yıldız; Coşkun, Funda; COŞKUN, NECMİYE FUNDA; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim Dalı.; 0000-0003-3604-8826; AAD-1271-2019
Caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), coronavirus disease 2019 (COVID-19) is a potentially fatal disease as a global public health issue. Several mechanisms may be involved in mortality. One of these is coagulopathy and disseminated intravascular coagulation caused by SARS-CoV-2. When patients have coagulation disorders, treatment becomes more challenging and mortality rate increases accordingly. The aim of this article is to review the potential mechanisms of coagulopathy in COVID-19 in light of literature data.
Comorbidies in patients hospitalized for acute exacerbation of copd
(Wiley, 2013-11-01) Dilektaşlı, Aslı Görek; Çetinoğlu, Ezgi Demirdoğen; Coşkun, Funda; Özkaya, Güven; Ege, Ercüment; Uzaslan, Esra; GÖREK DİLEKTAŞLI, ASLI; Çetinoğlu, Ezgi Demirdoğen; COŞKUN, NECMİYE FUNDA; ÖZKAYA, GÜVEN; Ege, Ercüment; UZASLAN, AYŞE ESRA; Uludağ Üniversitesi/Tıp Fakültesi/Biyostat Bölümü; Uludağ Üniversitesi/Tıp Fakültesi/Diş Bölümü; 0000-0001-7099-9647; 0000-0002-7400-9089; 0000-0003-3604-8826; 0000-0003-0297-846X; AAD-1271-2019; JPK-7012-2023; A-4421-2016; DTT-7416-2022; AAH-9812-2021; CPF-5844-2022; CDI-1977-2022
Development and validation of a simple risk scoring system for a COVİD-19 diagnostic prediction model
(Tüberküloz ve Toraks, 2023-01-01) Güçlü, Özge Aydın; Ursavaş, Ahmet; Ocakoğlu, Gokhan; Demirdogen, Ezgi; Öztürk, Nilufer Aylin Acet; Topçu, Dilara Ömer; Terzi, Orkun Eray; Onal, Uğur; Dilektaşlı, Aslı Görek; Sağlık, İmran; Coşkun, Funda; Ediger, Dane; Uzaslan, Esra; AkalIn, Halis; Karadağ, Mehmet; AYDIN GÜÇLÜ, ÖZGE; URSAVAŞ, AHMET; OCAKOĞLU, GÖKHAN; DEMİRDÖĞEN, EZGİ; ACET ÖZTÜRK, NİLÜFER AYLİN; ÖMER TOPÇU, DİLARA; TERZİ, ORKUN ERAY; ÖNAL, UĞUR; GÖREK DİLEKTAŞLI, ASLI; SAĞLIK, İMRAN; COŞKUN, NECMİYE FUNDA; EDİGER, DANE; UZASLAN, AYŞE ESRA; AkalIn, Halis; KARADAĞ, MEHMET; Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim Dalı; Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı; Uludağ Üniversitesi/Tıp Fakültesi/Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı; 0000-0003-1005-3205; 0000-0002-1114-6051; 0000-0002-7400-9089; 0000-0002-6375-1472; 0000-0001-7099-9647; 0000-0002-2954-4293; 0000-0001-7530-1279; 0000-0002-9027-1132; AAH-5180-2021; A-4970-2019; AAG-8744-2021; AAI-3169-2021; JCO-3678-2023; JPK-7012-2023
Introduction: In a resource-constrained situation, a clinical risk stratification system can assist in identifying individuals who are at higher risk and should be tested for COVID-19. This study aims to find a predictive scoring model to estimate the COVID-19 diagnosis.Materials and Methods: Patients who applied to the emergency pandemic clinic between April 2020 and March 2021 were enrolled in this retrospective study. At admission, demographic characteristics, symptoms, comorbid diseases, chest computed tomography (CT), and laboratory findings were all recorded. Development and validation datasets were created. The scoring system was performed using the coefficients of the odds ratios obtained from the multivariable logistic regression analysis.Results: Among 1187 patients admitted to the hospital, the median age was 58 years old (22-96), and 52.7% were male. In a multivariable analysis, typical radiological findings (OR= 8.47, CI= 5.48-13.10, p< 0.001) and dyspnea (OR= 2.85, CI= 1.71-4.74, p< 0.001) were found to be the two important risk factors for COVID-19 diagnosis, followed by myalgia (OR= 1.80, CI= 1.082.99, p= 0.023), cough (OR= 1.65, CI= 1.16-2.26, p= 0.006) and fatigue symptoms (OR= 1.57, CI= 1.06-2.30, p= 0.023). In our scoring system, dyspnea was scored as 2 points, cough as 1 point, fatigue as 1 point, myalgia as 1 point, and typical radiological findings were scored as 5 points. This scoring system had a sensitivity of 71% and a specificity of 76.3% for a cut-off value of >2, with a total score of 10 (p< 0.001).Conclusion: The predictive scoring system could accurately predict the diagnosis of COVID-19 infection, which gave clinicians a theoretical basis for devising immediate treatment options. An evaluation of the predictive
Diagnostic value of cervical mediastinoscopy: Report of 506 cases
(European Respiratory, 2013-09-01) Erol, Mehmet; Melek, Hüseyin; Bayram, Ahmet; Kermenli, Tayfun; Coşkun, Funda; Akyıldız, Elif; Gebitekin, Cengiz; Erol, Mehmet; MELEK, HÜSEYİN; BAYRAM, AHMET SAMİ; Kermenli, Tayfun; COŞKUN, NECMİYE FUNDA; AKYILDIZ, ELİF ÜLKER; GEBİTEKİN, CENGİZ; Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Cerrahisi Kliniği; Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Bölümü; Uludağ Üniversitesi/Tıp Fakültesi/Patholoji Bölümü; 0000-0003-0684-0900; 0000-0002-7371-4026; 0000-0003-3604-8826; AAE-1069-2022; AAD-1271-2019; AAI-5039-2021; JCE-0097-2023; ABB-7580-2020; KHO-7454-2024; A-6612-2019; IAV-7890-2023
Diagnostic value of video-assisted thoracoscopic lung biopsy on diagnosis of diffuse parenchymal lung dissease
(European Respiratory, 2013-09-01) Bayram, Ahmet Sami; Melek, Hüseyin; Erol, Mehmet Muharrem; Coşkun, Funda; Akyıldız, Elif Ülker; Gebitekin, Cengiz; BAYRAM, AHMET SAMİ; MELEK, HÜSEYİN; Erol, Mehmet Muharrem; COŞKUN, NECMİYE FUNDA; AKYILDIZ, ELİF ÜLKER; GEBİTEKİN, CENGİZ; Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Cerrahisi Anabilim Dalı; Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Bölümü; 0000-0003-0684-0900; 0000-0003-3604-8826; JCE-0097-2023; AAE-1069-2022; AAI-5039-2021; ABB-7580-2020; AAD-1271-2019; KHE-8874-2024; JHY-9777-2023
Did the smokers level of knowledge on copd changed in the last decade? Results of two surveys done on world copd days 2003 and 2013
(Wiley, 2015-12-01) Uzaslan, Esra; Dilektaşlı, Aslı Görek; Çetinoğlu, Ezgi Demirdoğen; Coşkun, Funda; Karadağ, Mehmet; UZASLAN, AYŞE ESRA; GÖREK DİLEKTAŞLI, ASLI; Çetinoğlu, Ezgi Demirdoğen; COŞKUN, NECMİYE FUNDA; KARADAĞ, MEHMET; Uludağ Üniversitesi; 0000-0001-7099-9647; 0000-0002-7400-9089; 0000-0003-3604-8826; 0000-0002-9027-1132; AAG-8744-2021; AAI-1004-2021; AAD-1271-2019; JPK-7012-2023; DTT-7416-2022; AAH-9812-2021
Different cases, different manifestations of post-covid-19 retinal artery occlusion: A case series
(Galenos Publ House, 2023-04-01) Yalçınbayır, Özgür; YALÇINBAYIR, ÖZGÜR; Gündüz, Gamze Uçan; UÇAN GÜNDÜZ, GAMZE; Coşkun, Funda; COŞKUN, NECMİYE FUNDA; Hakyemez, Bahattin; HAKYEMEZ, BAHATTİN; DOĞANAY, SELİM; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Oftalmloloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Pulmoloji Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Radyoloji Anabilim Dalı.; 0000-0002-7311-5277; 0000-0002-5458-1686; 0000-0003-3604-8826; IYJ-9408-2023; AAD-1271-2019; AAH-6225-2021
Coronavirus disease 2019 (COVID-19) is a procoagulant disease that increases the risk of clinically evident thrombotic complications. Herein we present 3 cases with different retinal artery occlusions that emerged soon after the diagnosis of COVID-19. The first patient had central retinal artery occlusion (CRAO) that resulted in visual loss in one eye. The second patient had inflammatory peripheral retinal artery occlusion, vasculitis, and uveitis which did not affect vision. The third patient presented with CRAO following the progression from orbital cellulitis to orbital apex syndrome. Interestingly, CRAO progressed to internal carotid artery occlusion in this case within days and resulted in monocular visual loss. Variations in the underlying pathophysiology and the characteristics of individual immune responses in patients with COVID-19 may be factors that determine differences in clinical manifestations. This article aims to describe different presentations of COVID-19-related retinal artery occlusions and discuss possible pathophysiological aspects.
Does concomitant extrapulmonary involvement changes characteristic features of pulmonary sarcoidosis?
(European Respiratory Soc Journals Ltd, 2013-09-01) Uzaslan, Esra; ACET ÖZTÜRK, NİLÜFER AYLİN; GÖREK DİLEKTAŞLI, ASLI; UZASLAN, AYŞE ESRA; Dilektaslı, Aslı Görek; Çetinoğlu, Ezgi Demirdöğen; Acet, Nilüfer Aylin; Coşkun, Funda; COŞKUN, NECMİYE FUNDA; URSAVAŞ, AHMET; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim; 0000-0001-7099-9647; 0000-0002-7400-9089; 0000-0002-6375-1472; 0000-0003-3604-8826; AAD-1271-2019; Z-1424-2019; AAI-1004-2021; JPK-7012-2023; AAI-3169-2021
Effects of the covid-19 pandemic on the follow-up and treatment of patients with idiopathic pulmonary fibrosis: A cross-sectional, multicentre phone call survey
(Bmj Publishing Group, 2021-01-01) Coskun, Funda; Hanta, Ismail; Cilli, Aykut; Ozkaya, Guven; Ursavas, Ahmet; Sevinc, Can; Ursavas, Ahmet; URSAVAŞ, AHMET; Coskun, Funda; COŞKUN, NECMİYE FUNDA; 0000-0003-3604-8826; AAD-1271-2019; AAI-3169-2021
Objective To learn about the attitudes and behaviours of patients with idiopathic pulmonary fibrosis (IPF) in relation to the difficulties experienced during the COVID-19 pandemic. Design A cross-sectional, multicentre phone call survey. Setting Four university hospitals in Turkey. Participants The study included patients with IPF receiving antifibrotics for at least 3 months and with doctor appointment and/or scheduled routine blood analysis between March and May 2020 (the first 3 months after the official announcement of the COVID-19 pandemic in Turkey). Interventions Phone calls (a 5 min interview) were performed in June 2020. A questionnaire and the Hospital Anxiety-Depression Scale were applied. Main outcome measures Patients' preferences for disease monitoring, patients' attitudes and behaviours towards IPF, drug continuation, COVID-19 diagnosis and anxiety/depression status. Results The study included 115 patients with IPF (82 male; mean age, 68.43 +/- 7.44 years). Of the patients, 73.9% had doctor appointment and 52.2% had scheduled routine blood testing; 54.5% of patients with doctor appointment self-cancelled their appointments and 53.3% of patients with scheduled routine blood testing did not undergo testing. Of the patients, 32.2% were on nintedanib and 67.8% were on pirfenidone; self-initiated drug discontinuation rate was 22.6%. The percentage of patients communicating with their physicians was 35.7%. The route of communication was by phone (34.8%). The frequency of depression and anxiety was 27.0% and 38.3%, respectively. The rates of drug discontinuation (35.1% vs 16.7%, p<0.05) and depression (37.8% vs 21.8%, p=0.07) were higher in nintedanib users than in pirfenidone users. Only two (1.7%) patients had COVID-19 diagnosis. Conclusions During the COVID-19 pandemic, a significant proportion (>50%) of patients self-cancelled their appointments and nearly a quarter of patients discontinued their medications. Providing a documentation of the problems experienced by patients with IPF about management of the necessary requirements during the COVID-19 pandemic, this study may be a model for patients with chronic diseases.
Evaluation of efficacy and safety of pirfenidone 200 mg tablets in patients with idiopathic pulmonary fibrosis in a real-life setting
(Tubitak Scientific & Technological Research Council Turkey, 2021-01-01) Cilli, Aykut; Hanta, Ismail; Sevinc, Can; Odemi, Ayse; Coskun, Necmiye Funda; COŞKUN, NECMİYE FUNDA; Ursavas, Ahmet; URSAVAŞ, AHMET; Bursa Uludağ Üniversitesi/Tıp Fakültesi.; 0000-0003-3604-8826; 0000-0002-4069-9181; AAI-3169-2021; AAD-1271-2019
Background/aim: Phase III trials have demonstrated a significant efficacy and an acceptable safety for pirfenidone in patients having mild to moderate idiopathic pulmonary fibrosis (IPF). Real-life data on the use of pirfenidone 200 mg tablets are limited. This study aimed to investigate the efficacy and safety of pirfenidone 200 mg tablets for the treatment of IPF in a real-life setting. Materials and methods: A retrospective, multicenter study conducted in four university hospitals in Turkey between January 2017 and January 2019. Clinical records of patients diagnosed with mild to moderate IPF and receiving pirfenidone (200 mg tablets, total 2400 mg/day) were reviewed retrospectively and consecutively. Pulmonary function measurements including forced vital capacity (FVC%) and diffusing capacity of the lungs for carbon monoxide (DLCO%) were analyzed at baseline and after 6-month of pirfenidone treatment. Descriptive statistics were expressed as mean, standard error or median (minimum-maximum), number and percentage, where appropriate. Results: The study included 82 patients, of whom 87.8% were males (mean age, 66 years). After 6-month of treatment, 7 patients discontinued the treatment. Of the remaining 75 patients, 71 (94.6%) remained stable, 4 (5.4%) had progressive disease as evident by a decline in the FVC% of at least 10% while on treatment, and 45 (61.3%) had improved cough. At least one adverse event (AE) associated with the treatment was observed in 28 (37.3%) patients. Conclusion: Pirfenidone 200 mg was effective and well tolerated and associated with relatively mild and manageable AEs in IPF patients.
Evaluation of fibrinogen levels in patients with obstructive sleep apnea syndrome
(Wiley, 2013-11-01) Çetinoğlu, Ezgi Demirdoğen; Ursavaş, Ahmet; Karadağ, Mehmet; Coşkun, Funda; Ediger, Dane; Uzaslan, Esra; Ege, Ercüment; Gözü, Oktay; Çetinoğlu, Ezgi Demirdoğen; URSAVAŞ, AHMET; KARADAĞ, MEHMET; COŞKUN, NECMİYE FUNDA; EDİGER, DANE; UZASLAN, AYŞE ESRA; Ege, Ercüment; Gözü, Oktay; Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Hastalıkları Anabilim Dalı.; 0000-0002-7400-9089; 0000-0002-9027-1132; 0000-0003-3604-8826; 0000-0002-2954-4293; AAI-3169-2021; AAD-1271-2019; AAG-8744-2021; JPK-7012-2023; AAE-9142-2019; AAH-9812-2021; CDI-1977-2022; CPF-5844-2022; JLC-5863-2023